Gossamer Bio (GOSS) Total Debt (2019 - 2026)
Gossamer Bio (GOSS) posted quarterly Total Debt of $9.6 million for Q1 2024, down 53.97% year-over-year from $20.8 million in Q2 2023, and down 22.84% quarter-over-quarter from $12.4 million in Q4 2023.
Gossamer Bio (GOSS) Total Debt (2019 - 2026) Analysis & Trends
Gossamer Bio's Total Debt history runs 6 years deep, the most recent figure standing at $9.6 million for Q1 2024.
- In Q1 2024, Total Debt fell 53.97% year-over-year to $9.6 million; the TTM figure through Mar 2024 stood at $9.6 million (down 53.97% YoY), while the FY2023 annual figure was $12.4 million, down 47.35% from the prior year.
- Total Debt for Q1 2024 stood at $9.6 million, down from $12.4 million in the prior quarter.
- The five-year high for Total Debt was $29.2 million in Q1 2022, with the low at $9.6 million in Q1 2024.
- The 5-year median for Total Debt is $28.5 million (2020), against an average of $23.0 million.
- The sharpest annual moves came in 2023 and 2024: Total Debt advanced 2.78% in 2023, then tumbled 53.97% in 2024.
- Gossamer Bio's Total Debt stood at $28.7 million in 2020, then grew by 1.17% to $29.1 million in 2021, then declined by 18.84% to $23.6 million in 2022, then sank by 47.35% to $12.4 million in 2023, then decreased by 22.84% to $9.6 million in 2024.
- Business Quant data shows GOSS's Total Debt at $9.6 million in Q1 2024, $12.4 million in Q4 2023, and $15.2 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.34 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 770.36 Mn |
| 10 | Gossamer Bio | 50.34 Mn | -6.69 Mn | - | 36.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.15 Mn |
| Mar 31, 2024 | 9.59 Mn |
| Dec 31, 2023 | 12.43 Mn |
| Sep 30, 2023 | 15.25 Mn |
| Jun 30, 2023 | 18.05 Mn |
| Mar 31, 2023 | 20.83 Mn |
| Dec 31, 2022 | 23.60 Mn |
| Sep 30, 2022 | 14.83 Mn |
| Jun 30, 2022 | 17.65 Mn |
| Mar 31, 2022 | 29.17 Mn |
| Dec 31, 2021 | 29.08 Mn |
| Sep 30, 2021 | 28.99 Mn |
| Jun 30, 2021 | 28.91 Mn |
| Mar 31, 2021 | 28.82 Mn |
| Dec 31, 2020 | 28.74 Mn |
| Sep 30, 2020 | 28.67 Mn |
| Jun 30, 2020 | 28.64 Mn |
| Mar 31, 2020 | 28.55 Mn |
| Dec 31, 2019 | 28.46 Mn |
| Sep 30, 2019 | 28.37 Mn |